Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions

Hepatocellular carcinoma (HCC) is the second deadliest cancer worldwide, due to its high incidence and poor prognosis. Frequent initial presentation at advanced stages along with impaired liver function limit the use of a broad therapeutic arsenal in patients with HCC. Although main HCC oncogenic dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hilmi, Marc, Neuzillet, Cindy, Calderaro, Julien, Lafdil, Fouad, Pawlotsky, Jean-Michel, Rousseau, Benoit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884868/
https://www.ncbi.nlm.nih.gov/pubmed/31783782
http://dx.doi.org/10.1186/s40425-019-0824-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884868/
https://www.ncbi.nlm.nih.gov/pubmed/31783782
http://dx.doi.org/10.1186/s40425-019-0824-5

Ejemplares similares